Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$95.48

52W Range

$47.79 - $114.99

50D Avg

$97.71

200D Avg

$85.22

Market Cap

$4.72B

Avg Vol (3M)

$965.40K

Beta

0.51

Div Yield

-

MIRM Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

334

IPO Date

Jul 18, 2019

Website

MIRM Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24	Dec 23
Product	$521.31M	$336.41M	$178.87M
License and Other Revenue	-	$479.00K	-
License Revenue	-	-	$7.50M

Fiscal year ends in Dec 25 | Currency in USD

MIRM Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$521.31M	$336.89M	$186.37M
Operating Income	$-22.14M	$-87.61M	$-109.15M
Net Income	$-23.36M	$-87.94M	$-163.41M
EBITDA	$-22.14M	$-48.97M	$-136.49M
Basic EPS	$-0.47	$-1.85	$-4.00
Diluted EPS	$-0.47	$-1.85	$-4.00

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 06, 26 | 12:00 AM

Q4 25Feb 25, 26 | 4:30 PM

Q3 25Nov 04, 25 | 4:30 PM

Peer Comparison

Ticker	Company
TLX	Telix Pharmaceuticals Limited
ADMA	ADMA Biologics, Inc.
BLTE	Belite Bio, Inc
TVTX	Travere Therapeutics, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
ACAD	ACADIA Pharmaceuticals Inc.
PRAX	Praxis Precision Medicines, Inc.
SLNO	Soleno Therapeutics, Inc.
LGND	Ligand Pharmaceuticals Incorporated
DYN	Dyne Therapeutics, Inc.